Sorry, you need to enable JavaScript to visit this website.

Study to Evaluate Safety of Axitinib in Combination with MK-3475 in Patients with Advanced Renal Cell Cancer

A phase 1b, open label, dose finding study to evaluate safety, pharmacokinetics and pharmacodynamics of Axitinib (AG-013736) in combination with Pembrolizumab (MK-3475) in patients with advanced renal cell cancer

Category & Conditions: Cancer
Medicine: INLYTA®(AXITINIB) Identifier (NCT): NCT02133742
Protocol ID: A4061079
Open Plain Language Summary Result: Click here